P845 ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2007, Vol.29, p.S216-S217
Main Authors: Corey, G.R, Stryjewski, M.E, O'Riordan, W.D, Fowler, V.G, Ross, D.P, Hopkins, A, Kitt, M.M, Barriere, S.L
Format: Article
Language:English
Subjects:
Infectious Disease
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0924-8579
1872-7913
DOI:10.1016/S0924-8579(07)70686-6